Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
Previous Symbol
CUSIPN/A
Phone45-8877-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio7.82
Quick Ratio7.82
Price-To-Earnings
Trailing P/E Ratio-8.40
Forward P/E Ratio-5.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.23 million
Price / Sales18.00
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book4.76
Profitability
EPS (Most Recent Fiscal Year)($1.48)
Net Income$-41,350,000.00
Net Margins-483.00%
Return on Equity-78.33%
Return on Assets-55.51%
Miscellaneous
Employees137
Outstanding Shares30,750,000
Market Cap$369.02 million
OptionableNot Optionable
ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions
What is ZEALAND PHARMA/S's stock symbol?
ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."
How were ZEALAND PHARMA/S's earnings last quarter?
ZEALAND PHARMA/S (NASDAQ:ZEAL) released its earnings results on Thursday, August, 16th. The company reported ($0.67) earnings per share (EPS) for the quarter. The firm had revenue of $2.42 million for the quarter. ZEALAND PHARMA/S had a negative return on equity of 78.33% and a negative net margin of 483.00%. View ZEALAND PHARMA/S's Earnings History.
When is ZEALAND PHARMA/S's next earnings date?
How can I listen to ZEALAND PHARMA/S's earnings call?
ZEALAND PHARMA/S will be holding an earnings conference call on Thursday, November 15th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 9294770448.
What price target have analysts set for ZEAL?
3 brokerages have issued 12 month price objectives for ZEALAND PHARMA/S's stock. Their predictions range from $29.00 to $29.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $29.00 in the next year. This suggests a possible upside of 133.3% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.
What is the consensus analysts' recommendation for ZEALAND PHARMA/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.
What are Wall Street analysts saying about ZEALAND PHARMA/S stock?
Here are some recent quotes from research analysts about ZEALAND PHARMA/S stock:
- 1. Needham & Company LLC analysts commented, "Zealand mgmt hosted a conference call today to discuss the sale of its lixisenatide revenue stream to $205M cash. All royalties and nearly all milestone payments from Sanofi will now be diverted to Royalty Pharma. Zealand retained its right to receive a milestone payment of $10-15M from Sanofi in 2020. Net proceeds to Zealand will be approximately $150M after factoring for redemption of $24.7M royalty bond and a 13.5% payment to Alkermes. Considering our modest sales projections for lixisenatide products, we believe the transaction is priced fairly. Zealand ended 2Q18 w/ $73.1M cash. Near-term milestones include results from dasiglucagon Phase 3 trial in Acute Severe Hypoglycemia as well as Phase 3 trial initiations for glepaglutide in and dasiglucagon in Congenital Hyperinsulinism." (9/7/2018)
- 2. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (3/15/2018)
Has ZEALAND PHARMA/S been receiving favorable news coverage?
Press coverage about ZEAL stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of ZEALAND PHARMA/S's key competitors?
Some companies that are related to ZEALAND PHARMA/S include Zogenix (ZGNX), Biohaven Pharmaceutical (BHVN), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Spectrum Pharmaceuticals (SPPI), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Esperion Therapeutics (ESPR), IMMURON Ltd/S (IMRN), Mirati Therapeutics (MRTX), Myovant Sciences (MYOV), Insmed (INSM), Tricida (TCDA) and Vanda Pharmaceuticals (VNDA).
Who are ZEALAND PHARMA/S's key executives?
ZEALAND PHARMA/S's management team includes the folowing people:
- Ms. Britt Meelby Jensen, CEO & Pres (Age 45)
- Mr. Mats Peter Blom M.B.A., MBA, Exec. VP & CFO (Age 53)
- Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 65)
- Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 53)
- Søren Vitfell Keller, Head of Legal Affairs
When did ZEALAND PHARMA/S IPO?
(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
How do I buy shares of ZEALAND PHARMA/S?
Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZEALAND PHARMA/S's stock price today?
One share of ZEAL stock can currently be purchased for approximately $12.43.
How big of a company is ZEALAND PHARMA/S?
ZEALAND PHARMA/S has a market capitalization of $369.02 million and generates $21.23 million in revenue each year. The company earns $-41,350,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. ZEALAND PHARMA/S employs 137 workers across the globe.
What is ZEALAND PHARMA/S's official website?
How can I contact ZEALAND PHARMA/S?
ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]
MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
